Spruce Biosciences reports FY2022 net loss $46.2M, cash $79.1M; pipeline updates

SPRUCE BIOSCIENCES, INC.

Net loss $46.2M for FY2022 vs $42.3M in 2021; R&D expenses $35.2M, G&A $12.1M.
Cash, equivalents and investments $79.1M as of Dec 31, 2022; additional $53.6M private placement closed Feb 2023.
CAHmelia-203 in adult classic CAH surpassed 50% enrollment; topline data expected H2 2023.
Strategic partnership with Kaken Pharmaceutical for tildacerfont in Japan; $15M upfront received; cash runway into 1H 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SPRUCE BIOSCIENCES, INC. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021..

Period: the year ended December 31, 2022
Net income: Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021.
Result: reported results

Exact text from the filing

Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the full year ended December 31, 2022 and providing corporate updates.

View on SEC.gov

Browse all earnings releases →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-008448

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.